488 related articles for article (PubMed ID: 22498320)
1. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
2. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study.
Wahlqvist ML; Lee MS; Chuang SY; Hsu CC; Tsai HN; Yu SH; Chang HY
BMC Med; 2012 Nov; 10():150. PubMed ID: 23194378
[TBL] [Abstract][Full Text] [Related]
4. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
[TBL] [Abstract][Full Text] [Related]
5. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
6. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
7. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
8. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
9. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
10. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
11. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
14. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
15. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
16. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
17. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
18. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
19. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus.
Evans JM; Doney AS; AlZadjali MA; Ogston SA; Petrie JR; Morris AD; Struthers AD; Wong AK; Lang CC
Am J Cardiol; 2010 Oct; 106(7):1006-10. PubMed ID: 20854965
[TBL] [Abstract][Full Text] [Related]
20. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]